| | Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancerReceived 13 February 2007; received in revised form 23 March 2007; accepted 26 March 2007. published online 24 April 2007.
|
Refers to corrigendum:
|
|
Corrigendum to “Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer” [Mol. Oncol. 1 (2007) 160–171]
, 22 January 2010
Bjørn Naume, Xi Zhao, Marit Synnestvedt, Elin Borgen, Hege Giercksky Russnes, Ole Christian Lingjærde, Maria Strømberg, Gro Wiedswang, Gunnar Kvalheim, Rolf Kåresen, Jahn M. Nesland, Anne-Lise Børresen-Dale, Therese Sørlie
Molecular Oncology
April 2010 (Vol. 4, Issue 2, Page 169)
Full Text |
Full-Text PDF (115 KB)
|
Add-Ons
|
Abstract Expression profiles of primary breast tumors were investigated in relation to disseminated tumor cells (DTCs) in bone marrow (BM) in order to increase our understanding of the dissemination process. Tumors were classified into five pre-defined molecular subtypes, and presence of DTC identified (at median 85 months follow-up) a subgroup of luminal A patients with particular poor outcome (p = 0.008). This was not apparent for other tumor subtypes. Gene expression profiles associated with DTC and with systemic relapse for luminal A patients were identified. This study suggests that DTC in BM differentially distinguishes clinical outcome in patients with luminal A type tumors and that DTC-associated gene expression analysis may identify genes of potential importance in tumor dissemination. a Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway b Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway c Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway d Institute for Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway e Department of Surgery, Ullevål University Hospital, Oslo, Norway f Laboratory for Cellular Therapy, Cancer Clinic, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway g Faculty of Medicine, University of Oslo, Norway Corresponding author. Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello 0310, Oslo, Norway. Tel.: +47 22934718; Fax: +47 22934440.
PII: S1574-7891(07)00014-2 doi:10.1016/j.molonc.2007.03.004 © 2007 Federation of European Biochemical Societies. Published by Elsevier Inc. All rights reserved. | |
|
|